



Performance of OssDsign Catalyst® in a patient with post-traumatic ankle arthritis showcased in medical journal

Uppsala, Sweden, September 2, 2025. OssDsign AB (publ.) today announces that a case study of OssDsign Catalyst® as a bone void filler to augment total ankle arthroplasty in a patient with post-traumatic ankle arthritis has been published in the Biomedical Journal of Scientific & Technical Research.

The rationale for the use of Catalyst Bone Graft for this patient, in addition to its ease of handling for the surgeon, was related to its mechanism of action, which includes both endochondral and intramembranous ossification. The authors conclude that at three months follow up, CT scans show excellent bony ingrowth through and around the entire tibia and talus implant surfaces.

"Our newly launched strategy 'ScaleToProfit' is focused on fully exploiting the potential of OssDsign Catalyst in the spine segment, however, in the longer perspective it also entails efforts to prepare for commercial expansion into adjacent indications for which OssDsign Catalyst is already cleared for use. We therefore welcome the publication of this positive case report in an extremity case, which confirms the potential for wider application of our nanosynthetic bone graft," comments Morten Henneveld, CEO of OssDsign.

The case report is published in the latest issue of the Biomedical Journal of Scientific & Technical Research (BJSTR) and is accessible here:

<http://biomedres.us/pdfs/BJSTR.MS.ID.009824.pdf>

About OssDsign Catalyst®

OssDsign Catalyst is a nanosynthetic bone graft that shows rapid and robust bone formation, even in poorly vascularized environments. OssDsign Catalyst's patented nanocrystalline structure and incorporated silicate ions, which mimic the body's natural bone, enable bone formation in the centre of the fusion mass. OssDsign Catalyst is designed to deliver a decreased non-union risk, making it highly applicable for both simple and complex patients.

The use of OssDsign Catalyst described in the publication may not be cleared in all markets. Please refer to the IFU for a full list of indications, contraindications, warnings, and precautions.

For further information, please contact:

Morten Henneveld, CEO, OssDsign AB

Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com

Certified Adviser:

The Company's Certified Adviser is DNB Carnegie Investment Bank AB.

About OssDsign®

OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve. The company has a strong presence in the U.S. market. OssDsign's share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.